Abstract
Background:
Myocardial fibrosis is one of the mechanisms underlying left ventricular (LV) dysfunction in obese patients and may result from dysregulation of extracellular matrix (ECM) turnover. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) represent a regulatory system playing a crucial role in ECM metabolism.
Objectives:
We sought to assess plasma levels of MMP-2, MMP-9, TIMP-1 and TIMP-2 in obese young women and to evaluate the association between MMP/TIMP system components and LV function in this population.
Design:
Prospective, cross-sectional study.
Setting:
University hospital.
Patients:
Seventy-one women aged <35 years with body mass index >30 kg m−2 and 30 healthy slim female controls.
Main outcome measures:
Plasma MMP-2, MMP-9, TIMP-1 and TIMP-2 measurements and echocardiographic studies, including LV strain/strain rate evaluation.
Results:
We demonstrated increased levels of MMP-9 and TIMP-1 and decreased MMP-2 in the obese population. LV dysfunction shown in patients with obesity was characterized by significantly lower values of strain/strain rate parameters. Plasma MMP-2 correlated positively and TIMP-1 negatively with systolic strain (r=0.39, P<0.001 and r=−0.40, P<0.001, respectively), peak systolic strain rate (r=0.38, P<0.001 and r=−0.27, P<0.03, respectively) and peak early diastolic strain rate (r=0.40, P<0.001 and r=−0.24, P<0.05, respectively). Plasma MMP-2, fasting insulin and body mass index proved the only independent determinants of strain/strain rate parameters of LV systolic and diastolic performance in obese subjects.
Conclusions:
In premenopausal obese women (1) plasma MMP/TIMP profile is altered, (2) abnormalities of LV function are related to the changes in the MMP/TIMP system that might promote attenuated ECM degradation, mainly to the downregulation of MMP-2.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP . The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195–1200.
Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305–313.
Dollery CM, McEwan JR, Henney AM . Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863–868.
McCawley L, Matrisian L . Matrix metalloproteinases: they're not just for matrix anymore!. Cur Opin Cell Biol 2001; 13: 534–540.
Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases. Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089–2096.
Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J . Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48: 89–96.
Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003; 108: 1455–1460.
Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM . Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Failure 2004; 10: 328–333.
Wang W, Schulze C, Suarez-Pinzon WL, Dyck JRB, Sawicki G, Schulz R . Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543–1549.
Tayebjee MH, Lim HS, Nadar S, MacFadyen RJ, Lip GYH . Tissue inhibitor of metalloproteinase-1 is a marker of diastolic dysfunction using tissue Doppler in patients with type 2 diabetes and hypertension. Eur J Clin Invest 2005; 35: 8–12.
Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR . Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002; 51: 1093–1101.
Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003; 278: 11888–11896.
Utian WH . The International Menopause Society menopause-related terminology definitions. Climacteric 1999; 2: 284–286.
Sahn DJ, DeMaria A, Kisslo J, Weyman A . Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083.
De Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH . Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994; 23: 600–606.
Spinale FG . Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520–530.
Chapman RE, Spinale FG . Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol 2004; 286: H1–H10.
Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001; 103: 2181–2187.
Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J . Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004; 44: 1609–1618.
Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley III AJ, Spinale FG . Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708–1715.
Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368–372.
Tazaki T, Minoguchi K, Yokoe T, Samson KTR, Minoguchi H, Tanaka A et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 170: 1354–1359.
Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM et al. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1173–1177.
Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P . Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110: 1564–1571.
Laimer M, Kaser S, Kranebitter M, Sandhofer A, Muhlmann G, Schwelberger H et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes Relat Metab Disord 2005; 29: 498–501.
Glowinska-Olszewska B, Urban M . Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007; 56: 799–805.
Shirwany A, Weber KT . Extracellular matrix remodeling in hypertensive heart disease. J Am Coll Cardiol 2006; 48: 97–98.
Zaman T, Fujii S, Goto D, Furomoto T, Mishima T, Nakai Y et al. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 2004; 37: 525–535.
Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res 2007; 30: 439–449.
Marwick TH, Wong CY . Role of exercise and metabolism in heart failure with normal ejection fraction. Prog Cardiovasc Dis 2007; 49: 263–274.
Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH . Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004; 110: 3081–3087.
Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GYH . Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004; 17: 770–774.
Noji Y, Shimizu M, Ino H, Higashikata T, Yamaguchi M, Nohara A et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004; 68: 355–360.
Lindsay MM, Maxwell P, Dunn FG . TIMP-1. A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136–141.
Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109: 2191–2196.
Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B et al. Alterations in left ventricular structure and function in young healthy obese women. J Am Coll Cardiol 2004; 43: 1399–1404.
Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Di Mario U, Leonetti F . Adapted changes in left ventricular structure and function in severe uncomplicated obesity. Obes Res 2004; 12: 1616–1621.
Di Bello V, Santini F, Di Cori A, Pucci A, Palagi C, Delle Donne MG et al. Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr 2006; 19: 1063–1071.
Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899–907.
Ahima RS . Adipose tissue as an endocrine organ. Obesity 2006; 14 (Suppl 5): 242S–249S.
Roberts CK, Won D, Pruthi S, Kurtovic S, Sindhu RK, Vaziri ND et al. Effects of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 2006; 100: 1657–1665.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kosmala, W., Plaksej, R., Przewlocka-Kosmala, M. et al. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int J Obes 32, 763–771 (2008). https://doi.org/10.1038/sj.ijo.0803794
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0803794
Keywords
This article is cited by
-
Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery
International Journal of Obesity (2022)
-
MMPs and TIMPs levels are correlated with anthropometric parameters, blood pressure, and endothelial function in obesity
Scientific Reports (2021)
-
Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects
Molecular Biology Reports (2016)
-
Emerging Markers of Atherosclerosis Before and After Bariatric Surgery
Obesity Surgery (2015)
-
Effect of Obesity on Growth‐related Oncogene Factor‐α, Thrombopoietin, and Tissue Inhibitor Metalloproteinase‐1 Serum Levels
Obesity (2010)